Company: TauRx Therapeutics
Drug Type: Small Molecule
Conditions: Alzheimer’s disease, bvFTD
Mechanism Type: Proteostasis, Aggregation Blocker
Mechanism: LMTX reduces levels of aggregated or misfolded Tau proteins according to preclinical studies. The active ingredient, methyltionininium, also targets aggregation of synuclein, TDP-43 and huntingtin.
U.S. Status for ALS: Preclinical
 Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. Harrington, CR et al. J Biol Chem. 2015 Apr 24;290(17):10862-75.
 TauRx Completes US$135m Financing Round to Support Phase 3 Clinical Trials Program in Alzheimer’s and Frontotemporal Dementia. PR Newswire, 8 Oct 2015. Accessed 11 March 2016 from http://www.prnewswire.com/news-releases/taurx-completes-us135m-financing-round-to-support-phase-3-clinical-trials-program-in-alzheimers-and-frontotemporal-dementia-531217421.html.
 Open-Label Study of TRx0237 in Subjects With Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia (bvFTD). ClinicalTrials.gov, 17 Sep 2014. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02245568.
Last updated March 11th, 2016